Prioridades de la investigación e innovación en cáncer en los países con ingresos medios y bajos
DOI:
https://doi.org/10.56050/01205498.2305Resumen
The World Bank classifies economies for analytical purposes into four income groups: low, lower-middle, upper-middle, and high-income. For this purpose, it uses gross national income (GNI) per capita data in U.S. dollars, converted from local currency using the World Bank Atlas (Figure 1), which is applied to smooth exchange rate fluctuations (1). Noncommunicable diseases (NCDs) were identified as one major challenge to sustainable development in low- and middle-income countries (LMICs). Most deaths globally are now due to NCDs, with cancer being responsible for at least 20 % of all mortality (2). Although the overall incidence of cancer is lower in LMICs compared with high-income countries (HICs), total cancer-related mortality is significantly higher in LMICs, especially for people ≤65 years of age; the more significant economic impact because of premature mortality and lost years of productivity is a particular problem for these limited resources environments (3). In 2020, 75 % of all global deaths attributable to NCDs, including cancer, occurred in LMICs, with nearly 50 % of deaths considered to be premature (4,5).
Biografía del autor/a
Liliana Gutiérrez, Centro de Tratamiento e Investigación sobre Cáncer (CTIC)
Institute for Research, Science and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia
Briegel de las Salas, Centro de Tratamiento e Investigación sobre Cáncer (CTIC)
Institute for Research, Science and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia
Natalia Sánchez, Centro de Tratamiento e Investigación sobre Cáncer (CTIC)
Institute for Research, Science and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia
Oscar Arrieta, Instituto Nacional de Cancerología – INCaN, México
Thoracic Oncology Unit, Instituto Nacional de Cancerología – INCaN, México City, México
Andrés F. Cardona, Centro de Tratamiento e Investigación sobre Cáncer (CTIC)
Institute for Research, Science and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia
Referencias bibliográficas
The World Bank. [Internet]. [Consultado marzo 3 de 2023]. Disponible en: https://datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html
WHO NCD mortality and morbidity. [Internet]. [Consultado marzo 3 de 2023]. Disponible en: https://www.who.int/gho/ncd/mortality_morbidity/en
Shah SC, Kayamba V, Peek RM Jr, Heimburger D. Cancer Control in Lowand Middle-Income Countries: Is It Time to Consider Screening? J Glob Oncol. 2019;5:1-8. doi: 10.1200/JGO.18.00200.
WHO The top 10 causes of death. [Internet]. [Consultado marzo 3 de 2023]. Disponible en: http://www.who.int/mediacentre/factsheets/fs310/en/index1.html
Sankaranarayanan R. Screening for cancer in low- and middle-income countries. Ann Glob Health. 2014;80:412-417.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660.
Ansari KK, Jha A. Causes of Cancer in the World: Comparative Risk Assessment of Nine Behavioral and Environmental Risk Factors. Cureus. 2022;14(9):e28875. doi: 10.7759/cureus.28875.
Schottenfeld D, Beebe-Dimmer J. The cancer burden attributable to biologic agents. Ann Epidemiol. 2015;25(3):183-7. doi: 10.1016/j.annepidem.2014.11.016.
Gelband H, Sankaranarayanan R, Gauvreau CL, Horton S, Anderson BO, Bray F, et al.; Disease Control Priorities-3 Cancer Author Group. Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: key messages from Disease Control Priorities, 3rd edition. Lancet. 2016;387(10033):2133-2144. doi: 10.1016/S0140- 6736(15)00755-2.
Pramesh CS, Badwe RA, Bhoo-Pathy N, Booth CM, Chinnaswamy G, Dare AJ, et al. Priorities for cancer research in low- and middle-income countries: a global perspective. Nat Med. 2022;28(4):649-657. doi: 10.1038/s41591-022-01738-x.
Wells JC, Sharma S, Del Paggio JC, Hopman WM, Gyawali B, Mukherji D, et al. An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries. JAMA Oncol. 2021;7(3):379-385. doi: 10.1001/jamaoncol.2020.7478.
Drake TM, Knight SR, Harrison EM, Søreide K. Global Inequities in Precision Medicine and Molecular Cancer Research. Front Oncol. 2018;8:346. doi: 10.3389/fonc.2018.00346.
Gössling G, Rebelatto TF, Villarreal-Garza C, Ferrigno AS, Bretel D, Sala R, et al. Current Scenario of Clinical Cancer Research in Latin America and the Caribbean. Curr Oncol. 2023;30(1):653-662. doi: 10.3390/curroncol30010050.
UNESCO Institute for Statistics . Research and Development Expenditure (% of GDP)—Latin America & Caribbean. UNESCO Institute for Statistics; Montreal, QC, Canada: 2021.
Access to cancer medicine in low-resource settings. Lancet Oncol. 2013;14(1):1. doi: 10.1016/S1470- 2045(12)70595-8.
Mathew A. Global Survey of Clinical Oncology Workforce. J Glob Oncol. 2018;4:1-12. doi: 10.1200/ JGO.17.00188.
Ciocca DR, Delgado G. The reality of scientific research in Latin America; an insider’s perspective. Cell Stress Chaperones. 2017;22(6):847-852. doi: 10.1007/s12192-017-0815-8.
Gómez HL, Pinto JA, Castañeda C, Vallejos CS. Current barriers for developing clinical research in Latin America: A cross-sectional survey of medical oncologists. Clin. Res. Trials. 2015;1:22–28. doi: 10.15761/ CRT.1000108.
da Silva RE, Amato AA, Guilhem DB, de Carvalho MR, Novaes MRCG. International Clinical Trials in Latin American and Caribbean Countries: Research and Development to Meet Local Health Needs. Front Pharmacol. 2018;8:961. doi: 10.3389/ fphar.2017.00961.
Ruiz-Patiño A, Cardona AF, Arrieta O, Rolfo C, Gómez HL, Raez LE, et al. Scientific publications in cancer: in Latin America, strong scientific networks increase productivity (the TENJIN study). J Clin Epidemiol. 2020;126:1-8. doi: 10.1016/j.jclinepi.2020.05.033.
Bray F, Ferlay J, Laversanne M, Brewster DH, Gombe Mbalawa C, Kohler B, et al. Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration. Int J Cancer. 2015;137(9):2060-71. doi: 10.1002/ ijc.29670.
Siddiqui AH, Zafar SN. Global Availability of Cancer Registry Data. J Glob Oncol. 2018;4:1-3. doi: 10.1200/JGO.18.00116.
Ranganathan P, Chinnaswamy G, Sengar M, Gadgil D, Thiagarajan S, Bhargava B, et al.; National Cancer Grid of India. The International Collaboration for Research methods Development in Oncology (CRe- DO) workshops: shaping the future of global oncology research. Lancet Oncol. 2021;22(8):e369-e376. doi: 10.1016/S1470-2045(21)00077-2.
Malekzadeh A, Michels K, Wolfman C, Anand N, Sturke R. Strengthening research capacity in LMICs to address the global NCD burden. Glob Health Action. 2020;13(1):1846904. doi: 10.1080/16549716.2020.1846904.
Munung NS, Mayosi BM, de Vries J. Equity in international health research collaborations in Africa: Perceptions and expectations of African researchers. PLoS One. 2017;12(10):e0186237. doi: 10.1371/ journal.pone.0186237.
Parker M, Kingori P. Good and Bad Research Collaborations: Researchers’ Views on Science and Ethics in Global Health Research. PLoS One. 2016 Oct 13;11(10):e0163579. doi: 10.1371/journal. pone.0163579.
Pitt C, Goodman C, Hanson K. Economic Evaluation in Global Perspective: A Bibliometric Analysis of the Recent Literature. Health Econ. 2016;25 Suppl 1(Suppl Suppl 1):9-28. doi: 10.1002/hec.3305.
Grol R. Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med Care. 2001;39(8 Suppl 2):II46-54. doi: 10.1097/00005650-200108002-00003.
Cómo citar
Descargas
Publicado
Número
Sección
Licencia
Copyright
ANM de Colombia
Los autores deben declarar revisión, validación y aprobación para publicación del manuscrito, además de la cesión de los derechos patrimoniales de publicación, mediante un documento que debe ser enviado antes de la aparición del escrito. Puede solicitar el formato a través del correo revistamedicina@anmdecolombia.org.co o descargarlo directamente Documento Garantías y cesión de derechos.docx
Copyright
ANM de Colombia
Authors must state that they reviewed, validated and approved the manuscript's publication. Moreover, they must sign a model release that should be sent.
